title: Paclitaxel induces significant changes in epidoxorubicin distribution in mice.
abstract: BACKGROUND
  Inhibition of Pgp can affect the distribution and the pharmacokinetics of anthracyclines, causing marked changes in their toxicity. Since both paclitaxel and cremophor are substrates of Pgp, it was hypothesized that they could modify the pharmacokinetics of anthracyclines in a similar fashion.
  
  
  OBJECTIVE
  To evaluate whether pretreatment of mice with cremophor or paclitaxel dissolved in cremophor could induce changes in the distribution of epidoxorubicin (EpiDx).
  
  
  METHODS
  Male CDF1 mice were treated with ethanol or cremophor or paclitaxel and 30 min later with EpiDx (15 mg/kg i.v.). EpiDx serum and tissue levels were determined at several time points after EpiDx treatment by high pressure liquid chromotagraphy (HPLC) assay coupled with fluorimetric detection.
  
  
  RESULTS
  Pretreatment with paclitaxel dissolved in cremophor induced a highly significant increase in EpiDx levels in all tissues examined including heart. At 8 h heart levels in mice treated with EpiDx alone, EpiDx and cremophor and EpiDx and paclitaxel were 8.3 micrograms/g, 10.9 micrograms/g and 16.7 micrograms/g (P < 0.01), respectively. Cremophor alone induced a similar increase in spleen EpiDx levels but had only a moderate effect on heart and lung EpiDx levels. Levels of doxorubicin (Dx) aglycone in kidney and liver of mice treated with paclitaxel and EpiDx were higher than those in mice treated with EpiDx alone.
  
  
  CONCLUSIONS
  A pharmacokinetic interaction between paclitaxel and EpiDx was clearly demonstrated in mice. The much higher tissue levels of EpiDx after paclitaxel pretreatment may be the reason for the increased toxicity of EpiDx when administered soon after paclitaxel.
authors.affiliation: Department of Oncology, Mario Negri Institute for Pharmacological Research, Milan, Italy.
authors.forename: T
authors.initials: T
authors.lastname: Colombo
authors.forename: O
authors.initials: O
authors.lastname: Gonzalez Paz
authors.forename: M
authors.initials: M
authors.lastname: Zucchetti
authors.forename: A
authors.initials: A
authors.lastname: Maneo
authors.forename: C
authors.initials: C
authors.lastname: Sessa
authors.forename: A
authors.initials: A
authors.lastname: Goldhirsch
authors.forename: M
authors.initials: M
authors.lastname: D'Incalci
authors.forename: M
authors.initials: M
authors.lastname: Maneo
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000493:pharmacokinetics*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D004317:Doxorubicin / Q000493:pharmacokinetics*; D004347:Drug Interactions; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D017239:Paclitaxel / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D004317:Doxorubicin; D017239:Paclitaxel